BEGIN:VCALENDAR PRODID:-//Microsoft Corporation//Outlook 16.0 MIMEDIR//EN VERSION:2.0 METHOD:PUBLISH X-MS-OLK-FORCEINSPECTOROPEN:TRUE BEGIN:VTIMEZONE TZID:Eastern Standard Time BEGIN:STANDARD DTSTART:16011104T020000 RRULE:FREQ=YEARLY;BYDAY=1SU;BYMONTH=11 TZOFFSETFROM:-0400 TZOFFSETTO:-0500 END:STANDARD BEGIN:DAYLIGHT DTSTART:16010311T020000 RRULE:FREQ=YEARLY;BYDAY=2SU;BYMONTH=3 TZOFFSETFROM:-0500 TZOFFSETTO:-0400 END:DAYLIGHT END:VTIMEZONE BEGIN:VEVENT CLASS:PUBLIC CREATED:20170424T161355Z DESCRIPTION:With the approval of drugs like Nivolumab and Pembrolizumab pat ients are\nalready feeling the impact of cancer immunotherapy. Still\, wit h each\nstep forward researchers are becoming increasingly aware of the\nc omplexity and unique challenges that come with each individual’s\ndiseas e. Given that not all patients respond to existing treatments\,\nthere is an enormous need to start looking at the next generation of\nimmunotherapy solutions. At Cambridge Healthtech Insitute’s Inaugural\nImPACT: Immuno therapy Progress and Clinical Treatments\, being held\nDecember 5-7\, 2017 in San Diego\, four cutting-edge conferences will\nshowcase what’s comi ng next in immunotherapy. \n \nConference Tracks Include:\n \nNeoantigen B ased Personalized Immunotherapies\nThe Microbiome in Cancer Immunotherapy\ nTargeting the Tumor Microenvironment\nTargeting Innate Immune Cells\n \nL earn more at www.ImPACTImmunotherapy.com\n DTEND;TZID="Eastern Standard Time":20171207T170000 DTSTAMP:20170424T161355Z DTSTART;TZID="Eastern Standard Time":20171205T070000 LAST-MODIFIED:20170424T161355Z LOCATION:Hilton San Diego Resort & Spa PRIORITY:5 SEQUENCE:0 SUMMARY;LANGUAGE=en-us:CHI's ImPACT: Immunotherapy Progress and Clinical Tr eatments TRANSP:OPAQUE UID:040000008200E00074C5B7101A82E0080000000020AC4C3EF4BCD201000000000000000 010000000A03CC90242E1374684FFD0C6B4E38552 X-ALT-DESC;FMTTYPE=text/html:

Wi th the approval of drugs like Nivolumab and Pemb rolizumab patients are already feeling the impact of cancer immunotherapy. Still\, with each step forward researchers are becoming increasingly awar e of the complexity and unique challenges that come with each individual&# 8217\;s disease. Given that not all patients respond to existing treatment s\, there is an enormous need to start looking at the next generation of i mmunotherapy solutions. At Cambridge Healthtech Insitute’\;s Inaugural < b>ImPACT: Immunotherapy Progress and Clinical Treatments\, bein g held December 5-7\, 2017 in San Diego\, four cutting-edge conferences wi ll showcase what’\;s coming next in immunotherapy.

 \;

Conference Tracks Include:

 \;

Neoantigen Based Personalized Immunotherapies

The M icrobiome in Cancer Immunotherapy

Targeting the Tumor Microenvironm ent

Targeting Innate Immune Cells

 \;< /p>

Learn more at www.ImPACTImmunotherapy.com

X-MICROSOFT-CDO-BUSYSTATUS:BUSY X-MICROSOFT-CDO-IMPORTANCE:1 X-MICROSOFT-DISALLOW-COUNTER:FALSE X-MS-OLK-AUTOFILLLOCATION:FALSE X-MS-OLK-CONFTYPE:0 BEGIN:VALARM TRIGGER:-PT15M ACTION:DISPLAY DESCRIPTION:Reminder END:VALARM END:VEVENT END:VCALENDAR